Xtant Medical Holdings, Inc.: insider trades · United States · SEC (Form 4)

About Xtant Medical Holdings, Inc.

Xtant Medical Holdings, Inc. (ticker: XTNT) is a U.S.-based medical technology company listed on NYSE American in the United States. Headquartered in Belgrade, Montana, the company develops, manufactures, and commercializes a portfolio centered on regenerative biologics and spinal implant systems, with an expanding presence in selected wound-care applications. Its products are used by orthopedic surgeons, spine surgeons, and other specialists treating spinal, musculoskeletal, and tissue-healing conditions. The business is positioned as an integrated supplier that can provide both biologic grafting solutions and fixation systems, which is attractive to hospitals, ambulatory surgery centers, and distributor channels seeking a broad procedural offering from a single vendor. Xtant’s roots trace back to its tissue-bank heritage and its close connection to Montana State University’s Center for Biofilm Engineering. That background remains important because it underpins the company’s emphasis on donor tissue processing, proprietary manufacturing, quality control, and traceability. Over time, Xtant has evolved into a more vertically integrated orthobiologics platform, with processing capabilities and commercialization infrastructure designed to support a broad range of regenerative products. Its biologics portfolio includes solutions for spinal fusion and bone regeneration, while its spinal implant line spans cervical, thoracolumbar, and interbody systems designed to work alongside its graft products. The company also markets wound-care-related biologic offerings, including more recently introduced amniotic products. From a competitive perspective, Xtant operates in a fragmented but demanding market where it competes against larger medical-device and orthobiologics peers. Its key differentiators are portfolio breadth in orthobiologics, the ability to pair implants with biologics, and its integrated supply chain from tissue recovery through distribution. Management has increasingly framed the company around biologics as the core of the franchise, which suggests a strategic shift toward higher-focus, potentially higher-margin segments. A major recent development was the 2025 announcement of definitive agreements to sell selected spinal implant assets, including Coflex and CoFix, as well as its non-U.S. businesses, to Companion Spine. That transaction reflects a strategic effort to sharpen the company’s focus on its core biologics platform and simplify the business mix. More recently, the company has highlighted new product launches and continued community-oriented initiatives in Montana. For investors, XTNT remains a specialty healthcare small cap with meaningful execution risk, but also with a clearer strategic identity around regenerative medicine and spine care.